



University of Groningen

## Trial by Dutch Laboratories for Evaluation of Non-Invasive Prenatal Testing.

van Schendel, Rachel V; Page-Christiaens, Lieve; Beulen, Lean; Bilardo, Catia M; de Boer, Marjon A; Coumans, Audrey B C; Faas, Brigitte H; van Langen, Irene M; Lichtenbelt, Klaske D; van Maarle, Merel C

*Published in:*  
Prenatal Diagnosis

*DOI:*  
[10.1002/pd.4941](https://doi.org/10.1002/pd.4941)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2016

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

van Schendel, R. V., Page-Christiaens, L., Beulen, L., Bilardo, C. M., de Boer, M. A., Coumans, A. B. C., ... Dutch NIPT Consortium (2016). Trial by Dutch Laboratories for Evaluation of Non-Invasive Prenatal Testing. Part II - Women's Perspectives. *Prenatal Diagnosis*, 36(12), 1091-1098.  
<https://doi.org/10.1002/pd.4941>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## ORIGINAL ARTICLE

# Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part II—women's perspectives<sup>†</sup>

Rachèl V. van Schendel<sup>1</sup>, G. C. (Lieve) Page-Christiaens<sup>2</sup>, Lean Beulen<sup>3</sup>, Catia M. Bilardo<sup>4</sup>, Marjon A. de Boer<sup>5</sup>, Audrey B. C. Coumans<sup>6</sup>, Brigitte H. Faas<sup>7</sup>, Irene M. van Langen<sup>8</sup>, Klaske D. Lichtenbelt<sup>9</sup>, Merel C. van Maarle<sup>10</sup>, Meryn V. E. Macville<sup>11</sup>, Dick Oepkes<sup>12</sup>, Eva Pajkrt<sup>13</sup>, Lidewij Henneman<sup>1\*</sup> and for the Dutch NIPT Consortium

<sup>1</sup>Department of Clinical Genetics, Section Community Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands

<sup>2</sup>Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>3</sup>Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>4</sup>Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>5</sup>Department of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, The Netherlands

<sup>6</sup>Department of Obstetrics and Gynaecology, Maastricht UMC+, Maastricht, The Netherlands

<sup>7</sup>Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>8</sup>Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>9</sup>Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>10</sup>Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands

<sup>11</sup>Department of Clinical Genetics, Maastricht UMC+, Maastricht, The Netherlands

<sup>12</sup>Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands

<sup>13</sup>Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, The Netherlands

\*Correspondence to: Lidewij Henneman. E-mail: l.henneman@vumc.nl

<sup>†</sup>Part of this paper was presented at the 19th International Conference on Prenatal Diagnosis and Therapy (2015) and the European Human Genetics Conference (2015).

## ABSTRACT

**Objective** To evaluate preferences and decision-making among high-risk pregnant women offered a choice between Non-Invasive Prenatal Testing (NIPT), invasive testing or no further testing.

**Methods** Nationwide implementation study (TRIDENT) offering NIPT as contingent screening test for women at increased risk for fetal aneuploidy based on first-trimester combined testing (>1:200) or medical history. A questionnaire was completed after counseling assessing knowledge, attitudes and participation following the Multidimensional Measure of Informed Choice.

**Results** A total of 1091/1253 (87%) women completed the questionnaire. Of these, 1053 (96.5%) underwent NIPT, 37 (3.4%) invasive testing and 1 (0.1%) declined testing. 91.7% preferred NIPT because of test safety. Overall, 77.9% made an informed choice, 89.8% had sufficient knowledge and 90.5% had positive attitudes towards NIPT. Women with intermediate (odds ratio (OR) = 3.51[1.70–7.22],  $p < 0.001$ ) or high educational level (OR = 4.36[2.22–8.54],  $p < 0.001$ ) and women with adequate health literacy (OR = 2.60[1.36–4.95],  $p = 0.004$ ) were more likely to make an informed choice. Informed choice was associated with less decisional conflict and less anxiety ( $p < 0.001$ ). Intention to terminate the pregnancy for Down syndrome was higher among women undergoing invasive testing (86.5%) compared to those undergoing NIPT (58.4%) ( $p < 0.001$ ).

**Conclusions** The majority of women had sufficient knowledge and made an informed choice. Continuous attention for counseling is required, especially for low-educated and less health-literate women. © 2016 The Authors. *Prenatal Diagnosis* published by John Wiley & Sons, Ltd.

Funding sources: Supported by a grant from the Netherlands Organisation for Health Research and Development (ZonMw, No. 200340002).

Conflicts of interest: Since 18 January 2016, Dr. Page-Christiaens has been employed as an Associated Medical Director at Illumina Inc. Dr. Oepkes previously participated in clinical research sponsored by Ariosa Diagnostics and Natera Inc.

## INTRODUCTION

Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidy has changed the landscape of prenatal screening worldwide.<sup>1</sup> NIPT

uses sequencing of cell-free DNA (cfDNA) in maternal plasma to screen for trisomy 21, 18 and 13 with a high accuracy in both high- and low-risk populations.<sup>2,3</sup> For women with an elevated

risk based on first-trimester or sequential screening, NIPT is considered a good follow-up test that prevents the need for invasive testing for most of them, thereby avoiding the risk of iatrogenic loss of pregnancy.<sup>4</sup> Invasive test confirmation is, however, still necessary because of potential false-positive NIPT results.

Although the advantages offered by NIPT have created a strong demand to implement this test, concerns have been raised regarding the potential impact on informed decision-making.<sup>5</sup> Both pregnant women and health professionals have expressed fears that NIPT might become routinized or that women might feel pressured to accept it.<sup>6–8</sup> This could potentially undermine the aim of prenatal screening, which is to enable pregnant women to make an autonomous reproductive choice.<sup>9</sup>

Informed choice is most commonly defined as a decision made with sufficient knowledge, consistent with the decision-maker's values and behaviorally implemented.<sup>10</sup> The ability to make an informed choice has been shown to be associated with beneficial psychological outcomes such as less decisional conflict regarding the choice.<sup>11,12</sup> To safeguard the process of informed decision-making, the need for comprehensive counseling on NIPT has been emphasized.<sup>9,13</sup>

On 1 April 2014, the Netherlands incorporated NIPT into their governmentally supported and healthcare-funded Fetal Trisomy Screening Program. This has been realized through a nationwide implementation study: the TRIDENT study (Trial by Dutch laboratories for Evaluation of Non-Invasive Prenatal Testing). NIPT is being offered as an additional choice to women with an elevated risk for fetal trisomy 21, 18 or 13 based on first-trimester combined testing (FCT) or based on medical history. In the Netherlands, around 27% of pregnant women decide to have FCT.<sup>14</sup>

The TRIDENT study had two main objectives. First, to evaluate the clinical impact (uptake, test performance, turn-around-time, pregnancy outcome), the results of which have been reported separately (Oepkes *et al.*<sup>15</sup> Paper Part I). In this second part, we report on women's preferences and decision-making (informed choice), decisional conflict and anxiety.

## METHODS

In the TRIDENT study, women at increased risk for fetal trisomy were referred for in-depth counseling to one of the eight Dutch Regional Prenatal Diagnosis Centers or their satellite centers ( $n=13$ ). Pregnant women were offered the choice between NIPT, invasive testing (chorionic villus sampling (CVS) or amniocentesis (AC)) or no further testing. Details on the TRIDENT study can be found in our separate paper Part I (Oepkes *et al.*<sup>15</sup>). In seven of the eight centers, women participating in the TRIDENT study during the first five months (1 April – 1 September 2014) were asked to fill out two questionnaires. Approval for the study was granted by the Dutch government through a Population Screening Act License (No. 350010-118701-PG) and local University Medical Ethics Committees.

## PARTICIPANTS

Pregnant women with an increased risk for fetal trisomy 21, 18 or 13 based on the results of the first-trimester combined test

(cut-off risk  $\geq 1:200$ ) or based on medical history (i.e. a prior pregnancy with a fetal trisomy 13, 18 or 21 or a parental balanced Robertsonian translocation with increased risk on T21 or T13) were considered eligible. Exclusion criteria were gestational age  $<10+0$  weeks,  $<18$  years old, inability to provide informed consent, multiple pregnancies, vanishing twin, nuchal translucency  $>3.5$  mm or other structural fetal anomalies, maternal history of malignancy or a known maternal chromosomal abnormality. All participants received a unique TRIDENT study number.

## INFORMATION AND COUNSELING

During the standard pre-test counseling, NIPT was discussed as an alternative option for invasive testing in the case of an FCT result indicating an elevated risk. All women were given oral counseling by obstetricians, maternal fetal medicine specialists or specially trained counselors. Women were also given written information on both NIPT and invasive diagnostic testing (CVS or AC). The following topics were addressed: test procedure (including risk of invasive testing); reporting time; test sensitivity for T21, 18 and 13; the meaning of an abnormal test result and the necessity to confirm abnormal NIPT results with invasive testing. Furthermore, a dedicated website (in Dutch) was launched ([www.meerovernipt.nl](http://www.meerovernipt.nl)) where women could find additional information or ask questions about NIPT and the TRIDENT study.

## PROCEDURE

The two questionnaires were designed by a multidisciplinary team of social scientists, psychologists, obstetricians and a clinical geneticist. Women were asked to fill out the first questionnaire (Q1) directly after counseling. This was done either on paper (six centers) or online (one center). Some counselors in three centers, however, only asked women choosing NIPT, and not those choosing invasive testing, to fill out the questionnaire. Because the overall number of women electing invasive testing was low, this study mostly reflects the findings of women choosing NIPT. The second questionnaire (Q2) was completed after women had received their test results. Only responses from the first questionnaire (Q1) are presented here.

## MEASURES

Q1 registered the indication for follow-up testing (abnormal FCT or medical history) and whether women would have had FCT if NIPT had not been available. Next, women were asked to indicate, from a list of options, the most important reason for preferring either NIPT, invasive testing or no further testing.

*Informed Choice* was measured using a modified Multidimensional Measure of Informed Choice (MMIC) developed by Marteau *et al.*<sup>10,11</sup> This method comprises the dimensions of knowledge, attitude and uptake. The measure was adapted to reflect the test options in the current study. Women's knowledge about NIPT was measured through a 5-item scale designed for this study (Supplementary Table S1). The questions covered information about NIPT's characteristics and implications of testing discussed in the information leaflet and during counseling. Women's knowledge of invasive testing

was not assessed, except for one question that addressed the accuracy of NIPT compared to invasive testing. Women's attitudes towards NIPT and invasive testing were each measured using a semantic differential 5-point scale with four bipolar adjective pairs based on van den Berg *et al.*<sup>12</sup>: negative–positive, difficult–easy, frightening–not-frightening and reassuring–not-reassuring. In terms of reliability, the NIPT attitude scale and invasive testing attitude scale were internally consistent (Cronbach's alpha = 0.79 and 0.85, respectively). The type of test women decided to have was anonymously assessed from the TRIDENT study laboratory database using the TRIDENT study number.

The extent to which women accepted the fact that NIPT does not give 100% certainty and the fact that invasive testing has a miscarriage risk were both measured on a 5-point scale (compressed to a 3-point scale (not acceptable; neutral; acceptable) in analysis). Women's attitude towards termination of pregnancy in the case of Down syndrome or trisomy 13 or 18 were both measured with a single item on a 5-point scale (compressed into a 3-point scale: probably not, maybe/maybe not and probably).

*Difficulties in decision-making or decisional conflict* was assessed by the Dutch version of the 16-item Decisional Conflict Scale (DCS) developed by O'Connor<sup>16</sup> and translated and validated by Koedoot *et al.*<sup>17</sup> Cronbach's alpha for the DCS was 0.97.

*State anxiety* was measured by a Dutch version of the six-item short form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).<sup>18,19</sup> Cronbach's alpha was 0.87.

*Health literacy* was measured by a Dutch version of Chew's set of brief screening questions,<sup>20</sup> translated and adapted by Fransen *et al.*<sup>21</sup> Cronbach's alpha was 0.68.

The following sociodemographic variables were assessed: age, parity, level of education, ethnicity, religion and level of religiousness (active/somewhat active; not active/not religious). Women were asked to indicate their gestational age and whether they had conceived naturally or via assisted reproductive technology (ART).

## DATA ANALYSIS

Descriptive analyses were used to describe women's characteristics. For the MMIC analysis, knowledge sumscores were dichotomized into sufficient or insufficient knowledge. Because no standard criteria for 'sufficient' or 'insufficient' knowledge are available, we decided that a cut-off of  $>2/5$  questions would constitute sufficient knowledge. Questionnaires of women who left more than two knowledge questions blank were excluded from analyses. If a woman only left one or two questions blank or checked the box 'I don't know' these were treated as incorrect answers. Attitude scores were categorized into positive, neutral or negative. Because people with a neutral attitude cannot be classified as either having a positive or a negative attitude towards NIPT, they were excluded from the analysis, as was proposed by van den Berg *et al.*<sup>12</sup> This is considered a better approach than the original application (dichotomization) of the MMIC attitude scale.<sup>22</sup> Attitude was then combined with NIPT uptake to assess value-consistency; women who chose NIPT and have a

positive attitude or women who declined NIPT and have a negative attitude were classified as value-consistent. NIPT acceptors with a negative attitude or NIPT decliners with a positive attitude were classified as value-inconsistent. Based on their knowledge and value-consistency, it was assessed whether women had made an informed choice; if a woman had sufficient knowledge and was classified as value-consistent, an informed choice had been made.<sup>10,11</sup> If women's knowledge was insufficient and/or they were classified as value-inconsistent, their choice was considered to be uninformed.

Differences between women who chose NIPT and women who chose invasive testing were evaluated using the Fisher's Exact Test. To evaluate variables associated with making an informed choice, univariate and multiple logistic regression was used with statistical significance set at  $p < 0.1$  and  $p < 0.05$ , respectively. A Mann–Whitney test was used (because of non-normality of the items) to determine differences in decisional conflict and anxiety between women making an informed or uninformed choice. All analyses were performed using SPSS version 20 for Windows (IBM Statistics for Windows, IBM, NY, USA).

## RESULTS

### Women's characteristics

In total, 1091/1253 pregnant women filled out Q1 (87% response). Women's characteristics are presented in Table 1; 61.5% of women were highly educated and 74.9% were of Dutch origin. The mean age was 35.9 years (range 21–45) and the mean gestational age was 14.0 weeks (range 9–34). The majority of women (86%) had been offered NIPT because of a high risk ( $\geq 1:200$ ) after FCT and 14% because of a medical history.

For the informed choice analysis using the MMIC, 52 questionnaires had to be excluded because of missing data on the attitude questions. Women with a neutral attitude ( $n = 367$ ) were excluded from analysis for the reasons mentioned above. Seven women left more than two knowledge questions blank, and these were excluded from analysis, resulting in a total sample of 665 participants used in the informed choice analysis.

### Test preference

In our sample of 1091 women, 1053 (96.5%) had NIPT, 37 women (3.4%) had invasive testing and one woman (0.1%) declined further testing. The main reason for preferring NIPT was its safety (91.7%) (Table 2). Almost half of the women who preferred invasive testing did so because of test accuracy (47.1%) and 35.3% did so because of faster test results. The only woman who refrained from testing did so to avoid anxiety.

Women who had invasive testing significantly more often had a very high a priori risk ( $\geq 1:10$ ), compared to women who had NIPT ( $p < 0.001$ ). There was no significant difference in age, level of education, parity, having a medical history and conception via ART between women who chose invasive testing and women who chose NIPT.

Table 1 Characteristics of participants (*n* = 1091)

Characteristics	<i>n</i> (%)
<b>Maternal age (y) (missing 7)</b>	
≤25	24 (2.2)
26–35	424 (39.1)
≥36	636 (58.7)
<b>Level of education<sup>a</sup> (missing 2)</b>	
Low	92 (8.4)
Intermediate	327 (30.0)
High	670 (61.5)
<b>Ethnicity<sup>b</sup> (missing 14)</b>	
Dutch	807 (74.9)
Other Western	129 (12.0)
Non-Western	141 (13.1)
<b>Religion<sup>c</sup> (missing 5)</b>	
None	679 (62.5)
Christian	321 (29.6)
Muslim	42 (3.9)
Hindu	14 (1.3)
Other	30 (2.8)
<b>Level of religiousness (missing 10)</b>	
(Somewhat) Active	205 (19.0)
Not active/not religious	876 (81.0)
<b>Health literacy<sup>d</sup> (missing 3)</b>	
Inadequate	93 (8.5)
Adequate	995 (91.5)
<b>Parity (missing 12)</b>	
0	407 (37.7)
1 or more	672 (62.3)
<b>Method of conception (missing 33)</b>	
Natural	903 (82.8)
Via assisted reproductive technology <sup>e</sup>	155 (14.2)
<b>Gestational age (weeks) (missing 14)</b>	
9–24	1067 (99.1)
≥25	10 (0.9)
<b>Indication for follow-up testing (missing 4)</b>	
FCT risk ≥1:200	935 (86.0)
Medical history <sup>f</sup>	152 (14.0)
<b>FCT risk for fetal trisomy (n.a. 152)</b>	
≥1:10	50 (5.3)
1:11–1:200	785 (83.7)
Unknown	104 (11.0)

FCT, first-trimester combined test; n.a., not applicable.

Numbers may not add up to the total because of missing values.

<sup>a</sup>Low: elementary school, lower level of secondary school, lower vocational training; Medium: higher level of secondary school, intermediate vocational training, High: high vocational training, university.<sup>23</sup>

<sup>b</sup>Ethnicity was categorized as Dutch, Other Western or Non-Western by the following algorithm: Dutch if both parents were born in the Netherlands; Other Western if at least one of their parents was born in Europe (excluding Turkey), North America, Oceania, Indonesia or Japan; and Non-Western if at least one of their parents was born in Africa, Latin America, Asia (excluding Indonesia and Japan) or Turkey. If both parents were born abroad, then by country of the mother.<sup>23</sup>

<sup>c</sup>Christian: Calvinism, Protestantism, Roman Catholic, Reformed and Baptism.

Other: for example, Jewish, Buddhist and Jehovah's witness.

<sup>d</sup>Inadequate health literacy if answered other than 'never' or 'occasionally' on one or more items, based on Chew *et al.*<sup>20</sup>

<sup>e</sup>Intrauterine insemination (IUI) (*n* = 47); *in vitro* fertilization (IVF) (*n* = 38); intra-cytoplasmic sperm injection (ICSI) (*n* = 26); preimplantation genetic diagnosis (PGD) (*n* = 14); ovulation induction (*n* = 12); other (*n* = 18).

<sup>f</sup>Previous child with a trisomy 21, 18 or 13 (*n* = 114), or other disorder (*n* = 17); ultrasound anomaly (*n* = 9); pregnant by intra-cytoplasmic sperm injection (ICSI) (*n* = 7); parental Robertsonian translocation (*n* = 5).

The majority of women (77%) undergoing NIPT found it acceptable that NIPT does not give 100% certainty, while only 27% of the women undergoing invasive testing found

this acceptable ( $p < 0.001$ ). In contrast, the fact that invasive testing was associated with an increased risk of miscarriage was acceptable to 73% of women undergoing invasive testing and to only 15.9% of women having NIPT ( $p < 0.001$ ) (Table S2).

#### Intentions in the case of an abnormal result

Intention to terminate the pregnancy for Down syndrome was higher among women who had invasive testing (86.5%) compared to those who had NIPT (58.4%) ( $p < 0.001$ ). This was also the case for trisomy 13 and 18, although less pronounced (94.6% vs 77.6%, respectively,  $p = 0.013$ ) (Table S2).

#### Informed choice

As shown in Table 3, 89.8% of all women had sufficient knowledge on NIPT, 90.5% had a positive attitude towards NIPT and 86.3% made a decision that was value-consistent. Women with intermediate or higher education were more likely to have sufficient knowledge about NIPT than those with a lower level of education ( $p < 0.001$ ). There was no significant difference in knowledge between women who had NIPT and women who had invasive testing. Answers to separate knowledge questions are presented in Supplementary Table S2.

Informed choice analysis showed that 77.9% of all women had made an informed choice for NIPT. Those who made an uninformed choice (22.1%) did so because of insufficient knowledge (8.4%), value-inconsistency (11.7%) or because they had both insufficient knowledge and a value-inconsistent decision (2%) (Table 4). All women who had invasive testing had a positive attitude towards NIPT and therefore, based on the criteria of the MMIC, were scored as having made a value-inconsistent choice. However, data showed that 78.6% of these women also had a positive attitude towards invasive testing, so their choice for invasive testing was value-consistent and thus probably not uninformed (this could not be calculated because women's knowledge about invasive testing was not measured). When women who had invasive testing were excluded from the analysis, the percentage of informed choice was 81%. There was no significant difference in informed choice between women who were offered testing because of high-risk FCT results and those who had a high risk based on their medical history. There was also no difference in rates of informed choice between the seven participating centers.

As shown in Table 5, univariate analysis revealed that women making an informed choice were significantly more likely to be ≥36 years old, have intermediate or higher education, have a low level of religiousness, have adequate health literacy and had heard of NIPT before participating in the study. Women of non-Western ethnicity were significantly less likely to make an informed choice. Multivariate analysis showed that women with an intermediate- (odds ratio (OR) = 3.51 [95%confidence interval (CI), 1.70–7.22],  $p < 0.001$ ) and high level of education (OR = 4.36 [95%CI, 2.22–8.54],  $p < 0.001$ ) and those having adequate health literacy (OR = 2.60 [95%CI, 1.36–4.95],  $p = 0.004$ ) were significantly more likely to make an informed decision.



Table 2 Reasons for preferring NIPT, invasive testing or no further testing

Test choice	Reason	n (%)
NIPT (n = 1053) (missing 55)	It's safe for my baby	915 (91.7)
	My doctor advised me to have NIPT	28 (2.8)
	It can be done early in pregnancy	21 (2.1)
	It's easy to do	17 (1.7)
	My partner wanted it	2 (0.2)
	Other reasons	15 (1.5)
Invasive testing (n = 37) (missing 3)	Test accuracy	16 (47.1)
	Faster test results	12 (35.3)
	It gives me more information about the unborn child	3 (8.8)
	My doctor advised me to have invasive testing	1 (2.9)
	Other reasons	2 (5.9)
No testing (n = 1)	(Follow-up) testing gives me anxiety	1 (100)

### Decisional conflict and anxiety

Women who made an uninformed choice experienced more decisional conflict (Median (Mdn) = 21.88) than women who made an informed choice (Mdn = 6.25),  $U = 26\,942$ ,  $p < 0.001$ ,  $r = -0.22$ . Moreover, women who made an uninformed choice (Mdn = 50.00) experienced more anxiety than those who made an informed choice (Mdn = 36.67),  $U = 18\,737$ ,  $p < 0.001$ ,  $r = -0.34$ .

### DISCUSSION

The majority of high-risk pregnant women preferred NIPT because it is safe for the child. Higher test accuracy and faster results were the most frequently mentioned reasons to prefer invasive testing. Most women had sufficient knowledge, a positive attitude towards NIPT and were able to make an informed choice. Women with an intermediate or high level of education and adequate health literacy were more likely to make an informed choice. Informed choice was associated with experiencing less decisional conflict and less anxiety.

Women choosing NIPT, as compared to those undergoing invasive testing, were less likely to accept the miscarriage risk of invasive testing and less often considered pregnancy termination for Down syndrome. This might imply that women opting for NIPT have different motives than women opting for invasive testing in that they want to prepare themselves for a child with Down syndrome and therefore prefer a risk-free test. Results from two questionnaire studies also showed that NIPT will probably be used more readily in women who just want to prepare themselves.<sup>24,25</sup> In a UK study, where women were offered NIPT as a second screening test through the National Health Service (NHS), 31% (13/42) of women with a confirmed diagnosis of Down syndrome after NIPT continued the pregnancy, compared to 7% (2/29) after direct invasive testing.<sup>26</sup> It needs to be established if this remains true once NIPT is fully incorporated in prenatal care. Women who had invasive testing significantly more often had a very high a priori risk ( $\geq 1:10$ ). In that case, it is understandable that they would prefer a test that is more accurate and delivers faster results, as was also concluded from a previous study in the US.<sup>27</sup>

Table 3 Description and characteristics of the informed choice measures

Measure	Description	Items	Reliability	Range	Mean (SD)	Cut-off	Outcome
Knowledge score	Knowledge about characteristics of NIPT and meaning of test results	Five correct/incorrect items	—	0–5	4.0 (1.1)	>2	Sufficient knowledge: 89.8%
Attitude scale	Attitude towards having NIPT	Four 5-point items	0.79	4–20	16.7 (3.5)	>14 = positive <sup>a</sup> <10 = negative <sup>a</sup>	Positive attitude: 90.5% Negative attitude: 9.5%
Test uptake	Whether the woman had NIPT or not	Based on laboratory records	—	—	—	—	Test uptake: 96.5%
Value-consistency	Consistency between value (attitude) and behavior (test uptake)	Calculated <sup>b</sup>	—	—	—	—	Value-consistent: 86.3%
Informed choice	A knowledgeable and value-consistent decision	Calculated <sup>c</sup>	—	—	—	—	Informed choice: 77.9%

SD, standard deviation.

<sup>a</sup>Attitudes were divided into three equal categories. Neutral attitudes (the middle category) ( $n = 367$ ) were excluded from the analysis.<sup>12</sup>

<sup>b</sup>Women who had a positive attitude towards NIPT and chose to have NIPT or women who had a negative attitude and chose not to have NIPT were classified as value-consistent.

<sup>c</sup>An informed choice was made if a woman had sufficient knowledge and made a value-consistent decision. In all other cases, the decision was labeled as uninformed.

Table 4 Types of informed and uninformed choice ( $n = 665$ )<sup>a</sup>

	Knowledge	Attitude	Uptake	<i>n</i>	%
Informed choice	Good	Positive	Yes	518	77.9
	Good	Negative	No	0	0
Uninformed choice	Good	Positive	No	22	3.3
	Good	Negative	Yes	56	8.4
	Poor	Positive	Yes	56	8.4
	Poor	Negative	No	0	0
	Poor	Positive	No	6	0.9
	Poor	Negative	Yes	7	1.1

<sup>a</sup>Typology based on Marteau *et al.*<sup>10</sup> Women with 'neutral attitudes' ( $n = 367$ ) were excluded from the analysis, based on van den Berg *et al.*<sup>12</sup>

In our study, the rate of informed choice among women who chose NIPT (81%) is somewhat lower to that shown in the recent UK NHS study (94% informed choice).<sup>22</sup> In our study, we also showed that most women choosing invasive testing made a value-consistent decision.

In line with previous studies,<sup>11,12</sup> the results of the present study underscore the importance of making an informed choice in connection with beneficial psychological outcomes such as experiencing less decisional conflict. In contrast to other studies,<sup>12,28</sup> we also found that the anxiety level was less high in women making an informed choice as compared to those making an uninformed choice.

The high rate of informed choice in our patient cohort most likely results from the intensive information and counseling that women received from counselors who were specially trained for the study. It is conceivable that the rate of informed choice decreases once NIPT is offered outside the study context. To safeguard informed decision-making, emphasis

has to be placed on further development of information tools and maintaining good counseling. The use of decision aids<sup>29,30</sup> or visual aids such as an informational film<sup>31</sup> may have a positive effect on informed decision-making by improving knowledge and assisting women in making decisions that are consistent with their values. Special attention should be given to women with a lower educational level and/or inadequate health literacy. A study among Latina women in the US showed that women with a lower level of education more often decline NIPT based on insufficient knowledge.<sup>32</sup> Moreover, women from ethnic minority groups less often make an informed choice about prenatal testing.<sup>33</sup> Diversifying the ways through which information is communicated might support informed decision-making,<sup>32</sup> for example, by providing written information in different languages<sup>33</sup> or using visual aids.

Because NIPT was offered as a contingent screening test, women (excluding those with an indication based on medical history) already had made the decision to have prenatal screening with FCT. This means that they had already reflected on prenatal testing before having to decide whether to have NIPT or not. To enable women to make an informed choice, counselors should discuss the advantages and disadvantages of both NIPT and invasive testing. When used as a first-tier screening test, the choice to accept or decline NIPT will become the first decision-making moment about prenatal screening, requiring additional training of counselors, and new patient material to be developed and tested for this situation.

The strength of this study is its large sample size. Participants were recruited nationwide, resulting in the inclusion of women from both urban and less urban areas. A weakness of the study is a possible underrepresentation of women who chose invasive testing instead of NIPT in some of the participating centers.

Table 5 Univariate and multiple logistic regression: factors associated with making an informed choice

Variable	Univariate logistic regression Informed choice ( $n = 665$ )			Multiple logistic regression Informed choice ( $n = 581$ ) <sup>a</sup>		
	Odds ratio	(95%CI)	<i>p</i> -Value <sup>b</sup>	Odds ratio	(95%CI)	<i>p</i> -Value <sup>c</sup>
<b>Age</b>						
≤25			0.014			0.113
26–35	2.85	(0.80–10.16)	0.106	1.50	(0.35–6.41)	0.592
≥36	4.29	(1.21–15.21)	0.024	2.25	(0.53–9.58)	0.275
<b>Level of education</b>						
Low			<0.001			<0.001
Intermediate	4.10	(2.11–7.98)	<0.001	3.51	(1.70–7.22)	<0.001
High	4.56	(2.46–8.44)	<0.001	4.36	(2.22–8.54)	<0.001
<b>Ethnicity</b>						
Dutch			0.005			0.181
Other Western	0.75	(0.45–1.26)	0.279	0.77	(0.43–1.38)	0.385
Non-Western	0.42	(0.25–0.71)	0.001	0.58	(0.32–1.06)	0.074
Low level of religiousness	1.60	(1.02–2.52)	0.041	1.23	(0.73–2.04)	0.438
Adequate health literacy	3.14	(1.77–5.57)	<0.001	2.60	(1.36–4.95)	0.004
Parity ≥1	0.96	(0.66–1.40)	0.838	—	—	—
Already heard of NIPT	2.28	(1.26–4.10)	0.006	1.90	(0.98–3.67)	0.056

CI, confidence interval.

<sup>a</sup>Multiple logistic regression excluded 84 women who had missing values on one of the variables.

<sup>b</sup>Statistical significance set at  $p < 0.1$ .

<sup>c</sup>Statistical significance set at  $p < 0.05$ .

Because no information was available on the survey decliners, potential selection bias cannot be excluded. Moreover, although the MMIC is often used as a measure of informed choice for screening, it does have some limitations. It requires a knowledge measure that is specific to the condition being tested, but because there is no gold standard for good knowledge this is subjective.<sup>34</sup> In our study, only knowledge on NIPT was assessed. To fully comprehend whether women made an informed choice, also knowledge of invasive testing should have been assessed. Another limitation of using the MMIC is that, because it is developed to measure informed choice between women either accepting or declining a test, it is unable to account for variations that exist when measuring informed choice between women choosing between different tests, as seen in our study with women who had both a positive attitude towards NIPT and invasive testing. Recently, the MMIC has been adapted and validated for women considering NIPT as a second screening test, also including women's deliberation.<sup>22</sup> Our sample predominantly comprised older, highly educated women. However, Dutch women are shown to be more likely to have prenatal screening if they are older and have above-average income.<sup>35</sup> Moreover, highly educated women often delay childbearing and are thus more likely to have a high risk result on the FCT. Finally, in the Netherlands, prenatal testing is offered in a nationally organized prenatal screening system, the uptake of which is relatively low (~27%),<sup>14</sup> and thus caution is needed when generalizing the results to other contexts, for example, to other countries.

In conclusion, implementation of NIPT within the setting of the TRIDENT study was successful as the knowledge of the vast majority of pregnant women on NIPT was sufficient and most were able to make an informed decision. Most women choose NIPT because they want a safe test. Compared to women having invasive testing, women who choose NIPT less frequently intend to terminate their pregnancy in the case of Down syndrome,

Edwards syndrome or Patau syndrome, possibly indicating that they more often undergo NIPT just to prepare themselves. To safeguard informed decision-making on NIPT outside the context of a controlled study, emphasis has to be placed on maintaining information and counseling skills among obstetric caregivers and exploring innovative strategies and counseling aids especially, but not exclusively, for women with low educational levels and/or inadequate health literacy.

## ACKNOWLEDGEMENTS

The authors wish to thank all women who took the time to complete the questionnaires. The participating centers are acknowledged for handing out the questionnaires. Prof. Danielle Timmermans and dr. Anke Kleinveld are acknowledged for giving advice on the questionnaire measures. The authors also like to thank all members of the Dutch NIPT Consortium.

### WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?

- NIPT is offered as alternative to invasive testing to screen pregnant women at high risk for fetal aneuploidy.
- Although NIPT has many advantages, concerns have been raised about the consequences for informed decision-making.

### WHAT DOES THIS STUDY ADD?

- Implementation of NIPT in a national healthcare-funded prenatal screening program, accompanied by pre-test counseling, results in most women having sufficient knowledge and making an informed choice
- Compared to women choosing invasive testing, women undergoing NIPT have less intention to terminate the pregnancy for Down syndrome.

## REFERENCES

1. Allyse M, Minear MA, Berson E, *et al.* Non-invasive prenatal testing: a review of international implementation and challenges. *Int J Womens Health* 2015;7:113–26.
2. Gil MM, Quezada MS, Revello R, *et al.* Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. *Ultrasound Obstet Gynecol* 2015;45:249–66.
3. Norton ME, Jacobsson B, Swamy GK, *et al.* Cell-free DNA analysis for noninvasive examination of trisomy. *N Engl J Med* 2015;372:1589–97.
4. Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. *Prenat Diagn* 2015;35:972–9.
5. de Jong A, Dondorp WJ, de Die-Smulders CEM, *et al.* Non-invasive prenatal testing: ethical issues explored. *Eur J Hum Genet* 2010;18:272–7.
6. van Schendel RV, Kleinveld JH, Dondorp WJ, *et al.* Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. *Eur J Hum Genet* 2014;22:1345–50.
7. Lewis C, Silcock C, Chitty LS. Non-invasive prenatal testing for Down's Syndrome: pregnant women's views and likely uptake. *Public Health Genomics* 2013;16:223–32.
8. Tamminga S, van Schendel RV, Rommers W, *et al.* Changing to NIPT as a first-tier screening test and future perspectives: opinions of health professionals. *Prenat Diagn* 2015;35:1316–23.
9. Dondorp W, de Wert G, Bombard Y, *et al.* Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. *Eur J Hum Genet* 2015;23:1438–50.
10. Marteau TM, Dormandy E, Michie S. A measure of informed choice. *Health Expect* 2001;4:99–108.
11. Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. *Patient Educ Couns* 2002;48:87–91.
12. van den Berg M, Timmermans DRM, ten Kate LP, *et al.* Are pregnant women making informed choices about prenatal screening? *Genet Med* 2005;7:332–8.
13. Sachs A, Blanchard L, Buchanan A, Bianchi DW. Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. *Prenat Diagn* 2015;35:968–71.
14. Atsma F, Jansen B, Liefers J. *Monitor 2013 screeningsprogramma downsyndroom en structureel echoscopisch onderzoek*. Nijmegen: Radboudumc/Scientific Institute for Quality of Healthcare; 2014.
15. Oepkes D, Page-Christiaens LC, Bax CJ, *et al.* Trial by Dutch laboratories for evaluation of Non-Invasive Prenatal Testing. Part I - clinical impact. *Prenat Diagn* 2016. DOI: 10.1002/pd.4945.
16. O'Connor AM. Validation of a Decisional Conflict Scale. *Medical Decision Making* 1995;15:25–30.
17. Koedoot N, Molenaar S, Oosterveld P, *et al.* The decisional conflict scale: further validation in two samples of Dutch oncology patients. *Patient Educ Couns* 2001;45:187–93.



18. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). *Br J Clin Psychol* 1992;31:301–6.
19. van der Bij AK, de Weerd S, Cikot RJLM, *et al.* Validation of the Dutch Short Form of the State Scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. *Publ Health Genomics* 2003;6:84–7.
20. Chew L, Bradley K, Boyko E. Brief questions to identify patients with inadequate health literacy. *Fam Med* 2004;36:588–94.
21. Fransen MP, Van Schaik TM, Twickler TB, Essink-Bot ML. Applicability of internationally available health literacy measures in the Netherlands. *J Health Commun* 2011;16:134–49.
22. Lewis C, Hill M, Skirton H, Chitty LS. Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy. *Eur J Hum Genet* 2016;24:809–16.
23. Statistics Netherlands [WWW document]. URL <http://www.cbs.nl/nl-NL/menu/home/default.htm>. [Accessed on 1 December 2015].
24. van Schendel RV, Dondorp WJ, Timmermans DR, *et al.* NIPT-based screening for Down syndrome and beyond: what do pregnant women think? *Prenat Diagn* 2015;35:598–604.
25. Verweij EJ, Oepkes D, de Boer MA. Changing attitudes towards termination of pregnancy for trisomy 21 with non-invasive prenatal trisomy testing: a population-based study in Dutch pregnant women. *Prenat Diagn* 2013;33:397–9.
26. Chitty LS, Wright D, Hill M, *et al.* Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units. *BMJ* 2016;354:i3426.
27. Taylor J, Chock V, Hudgins L. NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability. *J Genet Counsel* 2014;23:72–8.
28. Rowe HJ, Fisher JRW, Quinlivan JA. Are pregnant Australian women well informed about prenatal genetic screening? A systematic investigation using the Multidimensional Measure of Informed Choice. *Austr NZ J Obstet Gyn* 2006;46:433–9.
29. Kuppermann M, Pena S, Bishop JT, *et al.* Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. *JAMA* 2014;312:1210–7.
30. Beulen L, Van den Berg M, Faas BH, *et al.* The effect of a decision aid on informed decision making in the era of non-invasive prenatal testing: a randomized controlled trial. *Eur J Hum Genet* 2016;24:1409–16.
31. Bjorklund U, Marsk A, Levin C, Ohman SG. Audiovisual information affects informed choice and experience of information in antenatal Down syndrome screening—a randomized controlled trial. *Patient Educ Couns* 2012;86:390–5.
32. Farrell R, Hawkins A, Barragan D, *et al.* Knowledge, understanding, and uptake of noninvasive prenatal testing among Latina women. *Prenat Diagn* 2015;35:748–53.
33. Fransen MP, Essink-Bot ML, Vogel I, *et al.* Ethnic differences in informed decision-making about prenatal screening for Down's syndrome. *J Epidemiol Community Health* 2010;64:262–8.
34. Ames AG, Metcalfe SA, Archibald AD, *et al.* Measuring informed choice in population-based reproductive genetic screening: a systematic review. *Eur J Hum Genet* 2015;23:8–21.
35. Gitsels-van der Wal J, Verhoeven PS, Mannien J, *et al.* Factors affecting the uptake of prenatal screening tests for congenital anomalies; a multicentre prospective cohort study. *BMC Pregn Childbirth* 2014;14:1–12.

## SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web site.